Gemma N. Jones

2.6k total citations
21 papers, 893 citations indexed

About

Gemma N. Jones is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Gemma N. Jones has authored 21 papers receiving a total of 893 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 9 papers in Oncology and 5 papers in Genetics. Recurrent topics in Gemma N. Jones's work include DNA Repair Mechanisms (10 papers), PARP inhibition in cancer therapy (7 papers) and Mesenchymal stem cell research (3 papers). Gemma N. Jones is often cited by papers focused on DNA Repair Mechanisms (10 papers), PARP inhibition in cancer therapy (7 papers) and Mesenchymal stem cell research (3 papers). Gemma N. Jones collaborates with scholars based in United Kingdom, United States and Singapore. Gemma N. Jones's co-authors include M G Collis, Parminder Singh, J R Keddie, Peter W. R. Caulkett, Simon M. Poucher, Pascale V. Guillot, Dafni Moschidou, Hassan Abdulrazzak, Alan Lau and Emma Dean and has published in prestigious journals such as Journal of Clinical Oncology, Analytical Chemistry and Cancer Research.

In The Last Decade

Gemma N. Jones

20 papers receiving 876 citations

Peers

Countries citing papers authored by Gemma N. Jones

Since Specialization

Citations

This map shows the geographic impact of Gemma N. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gemma N. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gemma N. Jones more than expected).

Fields of papers citing papers by Gemma N. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gemma N. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gemma N. Jones. The network helps show where Gemma N. Jones may publish in the future.

Co-authorship network of co-authors of Gemma N. Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Gemma N. Jones. A scholar is included among the top collaborators of Gemma N. Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gemma N. Jones. Gemma N. Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CLDN18/CLDN18.2 IHC assay comparison (SP455, 43-14A, EPR19202) and co-prevalence expression with other biomarkers in gastric carcinoma. 2024 ·Journal of Clinical Oncology ·(unknown), Sophie E. Willis, (unknown), (unknown), (unknown), (unknown), Chris G. Richardson, Andrew G. Chambers, Yeoun Jin Kim, Tsu‐Shuen Tsao, Mark D. Robida, Jan Maciej Zaucha, Deborah L. Berry, Gemma N. Jones, Allison Barrett, Nicholas M. Durham, Marlon C. Rebelatto, Maria A.S. Broggi, Kenneth S. Thress, Nicolás A. Giraldo	1
2	Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models 2023 ·Cancers ·Ankur Karmokar, (unknown), Adina Hughes, (unknown), Zena Wilson, (unknown), (unknown), Elisabetta Leo, Gemma N. Jones, (unknown), Luis Tobalina, Emma Dean, Elaine Cadogan, Alan Lau	4
3	Epitope Lability of Phosphorylated Biomarkers of the DNA Damage Response Pathway Results in Increased Vulnerability to Effects of Delayed or Incomplete Formalin Fixation 2023 ·Journal of Histochemistry & Cytochemistry ·(unknown), (unknown), James Atkinson, (unknown), (unknown), Sophie E. Willis, Paul Waring, Jaime Rodriguez Canales, Gemma N. Jones	3
4	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study 2021 ·Clinical Cancer Research ·Timothy A. Yap, Matthew Krebs, Sophie Postel‐Vinay, (unknown), Jean‐Charles Soria, Juanita Lopez, Aliénor Berges, (unknown), Itziar Irurzun‐Arana, (unknown), Brunella Felicetti, Gemma N. Jones, Alan Lau, Paul Frewer, Andrew J. Pierce, Glen Clack, (unknown), Simon A. Smith, Emma Dean, Simon J. Hollingsworth	71
5	Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response 2021 ·British Journal of Cancer ·Sophie E. Willis, C Winkler, Martine P. Roudier, (unknown), Paola Marco‐Casanova, Emma V. Jones, Philip Rowe, Jaime Rodriguez‐Canales, Helen K. Angell, Felicia Ng, Paul Waring, Darren Hodgson, Jonathan A. Ledermann, Johanne I. Weberpals, Emma Dean, Elizabeth A. Harrington, J. Carl Barrett, Andrew J. Pierce, Elisabetta Leo, Gemma N. Jones	31
6	Evaluation of UV-C Decontamination of Clinical Tissue Sections for Spatially Resolved Analysis by Mass Spectrometry Imaging (MSI) 2021 ·Analytical Chemistry ·Andreas Dannhorn, Stephanie Ling, Steven J. Powell, Eileen McCall, Gareth Maglennon, Gemma N. Jones, Andrew J. Pierce, Nicole Strittmatter, Grégory Hamm, Simon T. Barry, Josephine Bunch, Richard J. A. Goodwin, Zoltán Takáts	5
7	SLFN11 informs on standard of care and novel treatments in a wide range of cancer models 2020 ·British Journal of Cancer ·C Winkler, Joshua Armenia, Gemma N. Jones, Luis Tobalina, Matthew J. Sale, Tudor Petreuş, (unknown), Violeta Serra, Anderson T. Wang, Alan Lau, Mathew J. Garnett, Patricia Jaaks, Elizabeth A. Coker, Andrew J. Pierce, Mark J. O’Connor, Elisabetta Leo	51
8	Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells 2020 ·Oncogene ·(unknown), Paul W.G. Wijnhoven, Antonio Ramos‐Montoya, Zena Wilson, Giuditta Illuzzi, (unknown), Gemma N. Jones, Neil H. James, Christophe D. Chabbert, Jonathan Stott, Emma Dean, Alan Lau, Lucy A. Young	126
9	Abstract 6168: Characterization of ATM inhibitor (AZD1390) distribution and pharmacodynamic changes in brain and glioblastoma in preclinical models to inform on mechanism of action 2020 ·Cancer Research ·Lenka Oplustil O’Connor, Grégory Hamm, (unknown), Stephanie Ling, Joanne Wilson, (unknown), Gareth Hughes, Sabina Cosulich, Wenlin Shao, Martin Pass, Gemma N. Jones, (unknown), Richard J. A. Goodwin, Mark J. O’Connor, Carl Barrett, Elizabeth A. Harrington	1
10	Multiplex Immunohistochemistry: The Importance of Staining Order When Producing a Validated Protocol 2019 ·(unknown), (unknown), Jesuchristopher Joseph, Gemma N. Jones, (unknown), Alan Sharpe, Garry Ashton, William Howat, Richard Byers, Helen K. Angell	9
11	Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients. 2018 ·Journal of Clinical Oncology ·Johanne I. Weberpals, Trevor J. Pugh, Glenwood D. Goss, Bernard Lo, (unknown), (unknown), Dax Torti, Jonathon Torchia, Prisni Rath, Alberto J. León, Kayla Marsh, Darren Hodgson, Gemma N. Jones, (unknown), William Howat, Paola Marco‐Casanova, Martine P. Roudier, (unknown), Harmanjatinder S. Sekhon	2
12	pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry 2018 ·British Journal of Cancer ·Gemma N. Jones, Claire Rooney, (unknown), Martine P. Roudier, Lucy A. Young, (unknown), Gareth Hughes, Jeffrey R. Whiteaker, Zena Wilson, Rajesh Odedra, Lei Zhao, Richard G. Ivey, William Howat, Elizabeth A. Harrington, J. Carl Barrett, Antonio Ramos‐Montoya, Alan Lau, Amanda G. Paulovich, Elaine Cadogan, Andrew J. Pierce	28
13	Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma 2018 ·Annals of Oncology ·Matthew Krebs, Juanita Lopez, Anthony B. El-Khoueiry, Yung‐Jue Bang, Sophie Postel‐Vinay, (unknown), Seock‐Ah Im, Leila Khoja, Nathan Standifer, Gemma N. Jones, Paola Marco‐Casanova, Paul Frewer, Aliénor Berges, (unknown), (unknown), Brunella Felicetti, Emma Dean, Andrew J. Pierce, Simon J. Hollingsworth	4
14	The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy 2017 ·Oncotarget ·Justin Greene, Anna Nguyen, Stacey M. Bagby, Gemma N. Jones, (unknown), Kevin S. Quackenbush, (unknown), Wells A. Messersmith, Kalpana Devaraj, Patrick J. Blatchford, S. Gail Eckhardt, Elaine Cadogan, Gareth Hughes, Aaron Smith, Todd M. Pitts, John J. Arcaroli	18
15	Counteracting bone fragility with human amniotic mesenchymal stem cells 2016 ·Scientific Reports ·Anna Maria Ranzoni, Michelangelo Corcelli, (unknown), Jemma G. Kerns, Maximilien Vanleene, Sandra J. Shefelbine, Gemma N. Jones, Dafni Moschidou, Benan Dala-Ali, Allen E. Goodship, Paolo De Coppi, Timothy R. Arnett, Pascale V. Guillot	21
16	Potential of Human Fetal Chorionic Stem Cells for the Treatment of Osteogenesis Imperfecta 2013 ·Stem Cells and Development ·Gemma N. Jones, Dafni Moschidou, Hassan Abdulrazzak, (unknown), Maximilien Vanleene, (unknown), Sandra J. Shefelbine, Nicole J. Horwood, Massimo Marenzana, Paolo De Coppi, J. H. Duncan Bassett, Graham R. Williams, Nicholas M. Fisk, Pascale V. Guillot	34
17	Human Mid-Trimester Amniotic Fluid Stem Cells Cultured Under Embryonic Stem Cell Conditions with Valproic Acid Acquire Pluripotent Characteristics 2012 ·Stem Cells and Development ·Dafni Moschidou, Sayandip Mukherjee, Michael P. Blundell, Gemma N. Jones, Anthony Atala, Adrian J. Thrasher, Nicholas M. Fisk, Paolo De Coppi, Pascale V. Guillot	51
18	Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues 2010 ·Journal of The Royal Society Interface ·Hassan Abdulrazzak, Dafni Moschidou, Gemma N. Jones, Pascale V. Guillot	103
19	Modelling TKI258 exposure and biomarker response in support of phase I dosing schedule finding 2008 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), M. Shi, Junfeng Xia, Gemma N. Jones, (unknown), (unknown), Horst Schran	4
20	The in vitro pharmacology of ZM 241385, a potent, non‐xanthine, A_2aselective adenosine receptor antagonist 1995 ·British Journal of Pharmacology ·Simon M. Poucher, J R Keddie, Parminder Singh, (unknown), Peter W. R. Caulkett, Gemma N. Jones, M G Collis	326

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact